Dendreon Corporation (DNDN) Release: PROVENGE® (sipuleucel-T) Data Presented at an Annual Scientific Urology Meeting
5/6/2013 12:38:10 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SEATTLE--(BUSINESS WIRE)--May 6, 2013--Dendreon Corporation (NASDAQ: DNDN) today announced the presentation of three PROVENGE® (sipuleucel-T) abstracts from new and ongoing clinical trials at the 2013 American Urological Association (AUA) Annual Meeting from May 4-8, 2013 in San Diego, California.
Help employers find you! Check out all the jobs and post your resume.
comments powered by